Lipum AB (publ) has published the interim report for period July to September for 2023. Below is a summary, a complete report (only in Swedish) is available on the company's website.
CEO Einar Pontén comments: “The multiple dosing of healthy subjects in our ongoing Phase 1 clinical trial was started according to plan.”
Financial summary January – September 2023
- Net sales: KSEK 0 (0)
- Result after financial items: KSEK -27 727 (-25 068)
- Cash and cash equivalents as of September 30: KSEK 17 551 (9 482)
Significant events during the period July – September 2023
- Capital contribution from rights issue 15.3 MSEK before overheads of 8%.
- Collaboration with researchers at Karolinska Institutet initiated.
- Publication of a scientific article on BSSL.
Significant events after the period
- Lipum's Phase 1 clinical trial advanced to multiple dosing and all eight subjects received their first dose.
CEO Einar Pontén comments on the report in a live webcast on October 31 at 09:00, link.